An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma
Clinical trial NCT02413489 · TERMINATED
Trial details
- NCT number
- NCT02413489
- Sponsor
- Janssen Research & Development, LLC
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-09-02
- Primary completion
- 2017-06-01
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.